title: Surgical margin in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
abstract: Two-hundred and forty adult patients with a high-grade soft tissue sarcoma were treated surgically in 18 hospitals participating in the Scandinavian Sarcoma Group Protocol I. The patients were randomized to either postoperative doxorubicin or control; patients whose surgical margin was judged marginal also received radiotherapy. The outcome after different surgical margins was analyzed in 185 tumors of Grades III or IV in the extremities. The total cumulative local tumor control was 91 percent (168 of 185) after a median of 47 months. The cumulative local control rates in the surgical groups were: compartmental or wide amputation--37/37 (100 percent), compartmental local excision--23/24 (96 percent), wide local excision--77/84 (92 percent), marginal excision and radiotherapy--19/21 (90 percent), and marginal excision alone (reevaluated margin)--12/19 (63 percent, significantly lower than others). The risk of local recurrence was 13 times higher after marginal than after compartmental surgery (P = 0.02) and 3 times higher if the tumor was larger than 10 cm (P = 0.05). The treatment with doxorubicin did not influence the risk of local recurrence. The survival rates did not differ significantly in the groups.
authors.affiliation: Orthopedic Service, Ullevål Hospital, University of Oslo, Norway.
authors.forename: A
authors.initials: A
authors.lastname: Alho
authors.forename: T A
authors.initials: TA
authors.lastname: Alvegård
authors.forename: O
authors.initials: O
authors.lastname: Berlin
authors.forename: J
authors.initials: J
authors.lastname: Ranstam
authors.forename: A
authors.initials: A
authors.lastname: Rydholm
authors.forename: B
authors.initials: B
authors.lastname: Rööser
authors.forename: B
authors.initials: B
authors.lastname: Stener
mesh_terms: D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012509:Sarcoma / Q000401:mortality / Q000601:surgery*; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate
chemical_list: D004317:Doxorubicin